Cefotetan-induced hemolytic anemia after perioperative prophylaxis.
Cephalosporin-induced hemolytic anemia is an acquired form of hemolytic anemia caused by interaction of drug with the immune system. Drug adsorption, drug-dependent antibody, and autoimmune induction are the three mechanisms of hemolysis. Cefotetan-induced hemolytic anemia (CIHA) has been described to occur through all three mechanisms. We report four cases of CIHA that occurred after appropriate perioperative use of cefotetan. All of our patients developed an acute and severe hemolytic episode that caused significant symptoms and led to hospitalization within 1-2 weeks after exposure to cefotetan. The hemolytic process was self-limited, and all our patients responded to supportive measures and blood transfusion. This report adds to our knowledge of CIHA, a rare complication of cefotetan use. Our cases suggest that cefotetan-induced acute severe hemolysis is caused by membrane modification (nonimmunologic protein adsorption) in addition to immune complex formation. Prompt diagnosis and aggressive supportive measures are essential in minimizing morbidity and mortality from hemolysis. Physicians should warn their patients about this complication. Given that hemolysis occurs when the subject is no longer under direct clinical supervision, patient awareness on how to recognize signs and symptoms of hemolysis is paramount to reducing the likelihood of this potentially lethal side effect. Finally, physicians might consider restricting cefotetan use.
Martin
Monte E
ME
Division of Hematology and Medical Oncology, University of Louisville, J.G. Brown Cancer Center, Kentucky 40202, USA. memart02@gwise.louisville.edu
Laber
Damian A
DA
D000328:Adult; D000743:Anemia, Hemolytic / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000936:Antigen-Antibody Complex / Q000097:blood; D001803:Blood Transfusion; D015313:Cefotetan / Q000008:administration & dosage / Q000009:adverse effects*; D004910:Erythrocyte Membrane / Q000378:metabolism; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007431:Intraoperative Complications / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy*; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D000936:Antigen-Antibody Complex; D015313:Cefotetan